[KLK] YoY Annual (Unaudited) Result on 30-Sep-2020 [#4]

Announcement Date
18-Nov-2020
Admission Sponsor
-
Sponsor
-
Financial Year
30-Sep-2020
Quarter
30-Sep-2020 [#4]
Profit Trend
YoY- 25.12%
View:
Show?
Annual (Unaudited) Result
30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 CAGR
Revenue 23,647,586 27,149,474 19,915,796 15,595,956 15,533,887 18,400,500 21,004,036 1.99%
PBT 1,152,227 3,219,478 2,976,425 1,185,730 823,928 1,117,380 1,450,205 -3.75%
Tax -161,530 -781,121 -524,373 -328,681 -173,195 -313,276 -383,329 -13.40%
NP 990,697 2,438,357 2,452,052 857,049 650,733 804,104 1,066,876 -1.22%
-
NP to SH 834,259 2,166,290 2,257,584 772,604 617,505 753,328 1,005,130 -3.05%
-
Tax Rate 14.02% 24.26% 17.62% 27.72% 21.02% 28.04% 26.43% -
Total Cost 22,656,889 24,711,117 17,463,744 14,738,907 14,883,154 17,596,396 19,937,160 2.15%
-
Net Worth 14,321,629 14,285,568 11,858,689 10,827,926 10,362,115 11,427,081 11,576,176 3.60%
Dividend
30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 CAGR
Div 215,687 215,631 215,612 161,771 159,744 159,744 532,482 -13.97%
Div Payout % 25.85% 9.95% 9.55% 20.94% 25.87% 21.21% 52.98% -
Equity
30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 CAGR
Net Worth 14,321,629 14,285,568 11,858,689 10,827,926 10,362,115 11,427,081 11,576,176 3.60%
NOSH 1,081,017 1,081,017 1,081,017 1,081,017 1,064,965 1,064,965 1,064,965 0.24%
Ratio Analysis
30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 CAGR
NP Margin 4.19% 8.98% 12.31% 5.50% 4.19% 4.37% 5.08% -
ROE 5.83% 15.16% 19.04% 7.14% 5.96% 6.59% 8.68% -
Per Share
30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 CAGR
RPS 2,192.77 2,518.14 1,847.37 1,446.11 1,458.63 1,727.80 1,972.27 1.78%
EPS 77.40 200.90 209.30 72.00 58.00 70.70 94.40 -3.25%
DPS 20.00 20.00 20.00 15.00 15.00 15.00 50.00 -14.15%
NAPS 13.28 13.25 11.00 10.04 9.73 10.73 10.87 3.39%
Adjusted Per Share Value based on latest NOSH - 1,081,017
30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 CAGR
RPS 2,151.76 2,470.41 1,812.20 1,419.12 1,413.47 1,674.31 1,911.22 1.99%
EPS 75.91 197.12 205.42 70.30 56.19 68.55 91.46 -3.05%
DPS 19.63 19.62 19.62 14.72 14.54 14.54 48.45 -13.97%
NAPS 13.0317 12.9989 10.7906 9.8526 9.4288 10.3978 10.5335 3.60%
Price Multiplier on Financial Quarter End Date
30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 CAGR
Date 29/09/23 30/09/22 30/09/21 30/09/20 30/09/19 28/09/18 29/09/17 -
Price 21.40 20.70 20.12 22.80 23.08 24.96 24.56 -
P/RPS 0.98 0.82 1.09 1.58 1.58 1.44 1.25 -3.97%
P/EPS 27.66 10.30 9.61 31.83 39.80 35.29 26.02 1.02%
EY 3.61 9.71 10.41 3.14 2.51 2.83 3.84 -1.02%
DY 0.93 0.97 0.99 0.66 0.65 0.60 2.04 -12.26%
P/NAPS 1.61 1.56 1.83 2.27 2.37 2.33 2.26 -5.49%
Price Multiplier on Announcement Date
30/09/23 30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 CAGR
Date 22/11/23 23/11/22 23/11/21 18/11/20 19/11/19 14/11/18 22/11/17 -
Price 21.52 21.20 20.26 23.32 22.50 24.92 24.50 -
P/RPS 0.98 0.84 1.10 1.61 1.54 1.44 1.24 -3.84%
P/EPS 27.82 10.55 9.67 32.55 38.80 35.23 25.96 1.15%
EY 3.59 9.48 10.34 3.07 2.58 2.84 3.85 -1.15%
DY 0.93 0.94 0.99 0.64 0.67 0.60 2.04 -12.26%
P/NAPS 1.62 1.60 1.84 2.32 2.31 2.32 2.25 -5.32%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment